Mizuho analyst Salim Syed lowered the firm’s price target on Cytokinetics (CYTK) to $84 from $103 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
- Cytokinetics presents additional data related to Aficamten
- Cytokinetics Announces Key Decisions at Annual Meeting
- Cytokinetics to host symposium on Contemporary Landscapes in Muscle Biology
- Buy Rating for Cytokinetics Driven by Promising Phase 3 Results of Aficamten in Hypertrophic Cardiomyopathy
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue